Cargando…
Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease
Substrate reduction therapy (SRT) has been proposed as a new gene therapy for Fabry disease (FD) to prevent the formation of globotriaosylceramide (Gb3). Nanomedicines containing different siRNA targeted to Gb3 synthase (Gb3S) were designed. Formulation factors, such as the composition, solid lipid...
Autores principales: | Beraza-Millor, Marina, Rodríguez-Castejón, Julen, Miranda, Jonatan, del Pozo-Rodríguez, Ana, Rodríguez-Gascón, Alicia, Solinís, María Ángeles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385692/ https://www.ncbi.nlm.nih.gov/pubmed/37514122 http://dx.doi.org/10.3390/pharmaceutics15071936 |
Ejemplares similares
-
Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease
por: Rodríguez-Castejón, Julen, et al.
Publicado: (2022) -
mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation
por: Gómez-Aguado, Itziar, et al.
Publicado: (2021) -
α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice
por: Rodríguez-Castejón, Julen, et al.
Publicado: (2021) -
Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA
por: Gómez-Aguado, Itziar, et al.
Publicado: (2020) -
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
por: Gómez-Aguado, Itziar, et al.
Publicado: (2020)